![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/09\/20260929_Adicet_Bio_Therapeutic_Indications-768x512.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Adicet Bio<\/p>\n Event Type<\/strong><\/p>\n Phase 1 Results<\/p>\n Modality<\/strong><\/p>\n Allogeneic Gamma-Delta CAR-T<\/p>\n Asset<\/strong><\/p>\n Prulacabtagene Leucel (Prula-cel)<\/p>\n Target<\/strong><\/p>\n CD20<\/p>\n Disease Area<\/strong><\/p>\n Systemic Lupus Erythematosus; Lupus Nephritis<\/p>\n Adicet reported Phase 1 data for prulacabtagene leucel, an allogeneic gamma-delta anti-CD20 CAR-T therapy, in systemic lupus erythematosus with or without lupus nephritis. At 12 months, 54% of evaluable patients achieved DORIS remission and 50% of evaluable lupus-nephritis patients achieved complete renal response. All patients discontinued immunosuppressants, and all but one reduced background steroids to no more than 5 mg prednisone equivalent. The signal is positive but early: only 22 patients were efficacy evaluable, 13 had at least 12 months of follow-up, and the trial was uncontrolled.<\/p>\n The August 28 data cut included 16 lupus-nephritis and six extra-renal lupus patients, with six to 21 months of follow-up. All had received at least three prior therapies. All 12-month responses were ongoing through the reported follow-up except one patient with urine protein-to-creatinine ratio of 0.65 g\/g who remained off immunosuppressants. Every efficacy-evaluable patient achieved B-cell depletion followed by naive-dominant B-cell reconstitution, and most biomarker-positive patients showed anti-dsDNA reduction or complement recovery.<\/p>\n Among 24 safety-evaluable participants, 25% had grade 1 or 2 cytokine-release syndrome and none had higher-grade CRS. No ICANS, IEC-HS, dose-limiting toxicity or graft-versus-host disease was reported. Infections occurred in 54%, including grade 3 or worse infections in 8.3%. FDA alignment supports outpatient administration and a single-arm pivotal study in lupus nephritis after inadequate response to at least two immunosuppressants, with double-digit enrollment and 12-month complete renal response as the primary endpoint.<\/p>\n CD20-directed depletion by an off-the-shelf gamma-delta CAR-T product could combine deep tissue B-cell removal with simplified manufacturing and reduced graft-versus-host risk. Naive-dominant reconstitution is consistent with immune reset, but it remains a biomarker pattern rather than proof of permanent tolerance. Relapse could emerge as autoreactive clones re-expand or antigen-negative compartments persist.<\/p>\n Immunosuppressant-free remission is a high-value outcome in a heavily pretreated population, and the safety profile is favorable relative to the most feared cell-therapy toxicities. However, steroid tapering, natural disease fluctuation, selection of treatment-responsive patients and a small single-arm design limit causal certainty. A very small pivotal trial can accelerate development but increases the importance of standardized endpoint adjudication, durable follow-up and post-approval confirmation.<\/p>\n Two interpretations remain plausible. The constructive view is that gamma-delta allogeneic CAR-T can reproduce the autoimmune-reset effects seen with autologous CD19 CAR-T while improving availability and outpatient feasibility. The competing view is that early responders and short follow-up overstate durability, while infections and repeat-dose constraints emerge later. Reproducible remission in a prespecified pivotal cohort, sustained drug-free renal response and consistent manufacturing would upgrade the thesis; relapses after B-cell return, opportunistic infection or lot variability would downgrade or falsify it.<\/p>\n Adicet Bio develops gamma-delta T-cell therapies. Lupus is an autoimmune disease in which pathogenic B-cell lineages contribute autoantibodies, immune-complex injury and organ inflammation; lupus nephritis affects the kidney and can lead to irreversible damage. Prula-cel is an allogeneic gamma-delta T-cell product engineered with an anti-CD20 CAR to deplete B cells. The platform aims to provide an inventory-based product with lower graft-versus-host potential than conventional alpha-beta allogeneic T cells.<\/p>\n Prula-cel is a credible platform-level validation for allogeneic autoimmune CAR-T because the dataset combines drug-free clinical responses, biological reconstitution and manageable early safety. The evidence is not yet sufficient to conclude that an off-the-shelf product matches autologous durability or eliminates inpatient risk. The unusually small proposed pivotal design raises both upside and scrutiny: endpoint discipline and long follow-up will matter more than headline response rates.<\/p>\n Signal Importance: 5 of 5. Signal Direction: positive for the reported early outcomes. Confidence in Facts: high. Confidence in Interpretation: moderate because the dataset is small, single-arm and company-reported. Red-team conclusion: the evidence supports clinical activity and a plausible immune reset, not yet comparative efficacy, permanent tolerance or treatment-ready scalability.<\/p>\n","protected":false},"excerpt":{"rendered":" Adicet reported Phase 1 data for prulacabtagene leucel, an allogeneic gamma-delta anti-CD20 CAR-T therapy, in systemic lupus erythematosus with or without lupus nephritis. At 12 months, 54% of evaluable patients achieved DORIS remission and…<\/p>\n","protected":false},"author":1,"featured_media":3517,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[490,583,209,888],"class_list":["post-3507","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-adicet-bio","tag-car-t","tag-lupus-nephritis","tag-prula-cel"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3507","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3507"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3507\/revisions"}],"predecessor-version":[{"id":3522,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3507\/revisions\/3522"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3517"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3507"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3507"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3507"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n